Biomarkers In Prediction of Acute Mesenteric Ischaemia (BIPAMI): a prospective multicentre international study

Background: Available evidence on biomarkers of acute mesenteric ischaemia (AMI) is limited due to unclear reporting of AMI mechanisms, localization and severity and random time points for biomarker sampling. The primary aim of this study was to identify a combination of biomarkers allowing accurate identification of transmural AMI, the primary determinant of outcome. Methods: In this prospective multicentre study, consecutive adult patients admitted with suspected AMI during one-year recruitment period were included before any AMI-directed intervention. Serial blood samples were collected during up to 72 hours from admission. Intestinal fatty acid-binding protein (iFABP), alpha-glutathione S-transferase (alpha- GST), ischaemia-modified albumin (IMA), D-lactate, signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1), lipopolysaccharide-binding protein (LBP), interleukin 6 (IL-6), procalcitonin, D-dimers, acid-base status, lactate, C-reactive protein (CRP), white blood cell count, creatinine and troponin were analysed. Biomarker accuracy was assessed by ROC analysis. Optimal biomarker combination was determined by exhaustive logistic regression modelling and cut-offs by multi-objective (Pareto) optimization. Internal validation was performed using bootstrap resampling. Results: Thirteen sites from six European countries included in total 256 patients, among them 86 without AMI, 158 with AMI and 12 with strangulating bowel obstruction identified only after study inclusion. No individual biomarker or biomarker combination accurately distinguished AMI from non-AMI. However, among patients with classical AMI (arterial occlusive, venous and non-occlusive mesenteric ischaemia [NOMI]), a combination of five biomarkers (IL-6, alpha-GST, CRP, Scube-1 and blood lactate) discriminated transmural (n=86) from non-transmural AMI (n=39) with AUC of 0.872 (0.802-0.942), positive likelihood ratio of 5.52 and negative likelihood ratio of 0.18. The presence of at least two of the following biomarkers above threshold values correctly classified 106/125 (85%) patients: IL-6 >130 ng/L, alpha-GST >2200 µg/L, CRP >180 mg/L, SCUBE-1 >22 µg/L, blood lactate >5.5 mmol/L. Conclusions: Although biomarkers could not reliably distinguish AMI from non-AMI in patients presenting with suspected disease, a five-biomarker panel identified transmural bowel injury with acceptable accuracy. These findings suggest that circulating biomarkers primarily reflect the extent of intestinal injury and necrosis rather than the presence of AMI itself, making them potentially valuable for identification of AMI patients with irreversible bowel damage requiring urgent intervention. Study registration: NCT06212921 (Registration Date 19–01-2024).

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11610148/v1
Primary Topic
Abdominal vascular conditions and treatments
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Biomarkers In Prediction of Acute Mesenteric Ischaemia (BIPAMI): a prospective multicentre international study

Elisabetta Roberti, Elina Sor, Giada Bracalente, Hiie Soeorg et al.
1 links
Research Square
Abdominal vascular conditions and treatments
preprint

Biomarkers In Prediction of Acute Mesenteric Ischaemia (BIPAMI): a prospective multicentre international study

Elisabetta Roberti, Elina Sor, Giada Bracalente, Hiie Soeorg, Vladislav Mihnovitš, Maani Hakimi, Antonella Cotoia, Simone Piva, Marko Murruste, Anneli Aus, Stefan Acosta, Valerio Cozza, Ingrida Lisauskienė, Kadri Tamme, Mindaugas Šerpytis, Algimantas Tamelis, Manuela Mastronardi, Alan Biloslavo, Henrikas Paužas, Juan Antonio Celi de la Torre, Yasmin Soltanzadeh-Naderi, Salvatore Notaro, Dumitru Casian, Diego Visconti, Eugenio Piscitelli, Annika Reintam Blaser, Kalle Kisand, Alessandra Marano, Joel Starkopf, Anna-Liisa Voomets, Mildred Mustkivi, Michèle Schöb, Nicola Curlo, Meis Jawad, Karl Kustav Kuning, BIPAMI study group, Merli Koitmäe
preprint en

Abstract

Background: Available evidence on biomarkers of acute mesenteric ischaemia (AMI) is limited due to unclear reporting of AMI mechanisms, localization and severity and random time points for biomarker sampling. The primary aim of this study was to identify a combination of biomarkers allowing accurate identification of transmural AMI, the primary determinant of outcome. Methods: In this prospective multicentre study, consecutive adult patients admitted with suspected AMI during one-year recruitment period were included before any AMI-directed intervention. Serial blood samples were collected during up to 72 hours from admission. Intestinal fatty acid-binding protein (iFABP), alpha-glutathione S-transferase (alpha- GST), ischaemia-modified albumin (IMA), D-lactate, signal peptide-CUB-EGF domain-containing protein 1 (SCUBE-1), lipopolysaccharide-binding protein (LBP), interleukin 6 (IL-6), procalcitonin, D-dimers, acid-base status, lactate, C-reactive protein (CRP), white blood cell count, creatinine and troponin were analysed. Biomarker accuracy was assessed by ROC analysis. Optimal biomarker combination was determined by exhaustive logistic regression modelling and cut-offs by multi-objective (Pareto) optimization. Internal validation was performed using bootstrap resampling. Results: Thirteen sites from six European countries included in total 256 patients, among them 86 without AMI, 158 with AMI and 12 with strangulating bowel obstruction identified only after study inclusion. No individual biomarker or biomarker combination accurately distinguished AMI from non-AMI. However, among patients with classical AMI (arterial occlusive, venous and non-occlusive mesenteric ischaemia [NOMI]), a combination of five biomarkers (IL-6, alpha-GST, CRP, Scube-1 and blood lactate) discriminated transmural (n=86) from non-transmural AMI (n=39) with AUC of 0.872 (0.802-0.942), positive likelihood ratio of 5.52 and negative likelihood ratio of 0.18. The presence of at least two of the following biomarkers above threshold values correctly classified 106/125 (85%) patients: IL-6 >130 ng/L, alpha-GST >2200 µg/L, CRP >180 mg/L, SCUBE-1 >22 µg/L, blood lactate >5.5 mmol/L. Conclusions: Although biomarkers could not reliably distinguish AMI from non-AMI in patients presenting with suspected disease, a five-biomarker panel identified transmural bowel injury with acceptable accuracy. These findings suggest that circulating biomarkers primarily reflect the extent of intestinal injury and necrosis rather than the presence of AMI itself, making them potentially valuable for identification of AMI patients with irreversible bowel damage requiring urgent intervention. Study registration: NCT06212921 (Registration Date 19–01-2024).

Research Square
Università Cattolica del Sacro Cuore (IT), University of Foggia (IT), Lithuanian University of Health Sciences (LT), Vilnius University (LT), Lund University (SE), Tartu University Hospital (EE), Agostino Gemelli University Polyclinic (IT), Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT), North Estonia Medical Centre (EE), Ospedale di Cattinara (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Luzerner Kantonsspital (CH), Nicolae Testemițanu State University of Medicine and Pharmacy (MD), Policlinico Universitario di Catania (IT), Ospedale Monaldi (IT), University of Tartu (EE), University of Brescia (IT)
Eesti Teadusagentuur
Good health and well-being
Abdominal vascular conditions and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon